Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30206685 | 1.00 | CFD (0.45) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL19640041 | 0.86 | CYP4F2 (0.58) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL11094901 | 0.86 | AKT1 (0.52) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL30206746 | 0.84 | CFD (0.49) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL19640118 | 0.84 | CFD (0.49) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL15110816 | 0.79 | ERN1 (0.50) | CFDPTGS1TSHRKDM4EALDH1A1 | |
| SCHEMBL810128 | 0.78 | PTGS1 (0.51) | CFDPTGS1CYP4F2CYP4A11ALOX5 | |
| SCHEMBL11464187 | 0.77 | SRC (0.47) | CFDTSHRKDM4EALDH1A1GAA | |
| SCHEMBL21807289 | 0.77 | ALDH1A1 (0.47) | CFDPTGS1CYP4F2CYP4A11TSHR | |
| SCHEMBL3437173 | 0.77 | KDM4E (0.53) | CFDTSHRKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230048560-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2023-02-16 | — | — | US | disclosed |
| CN-109415353-B | Pegylated carfilzomib compounds | 美国安进公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
| CN-111344018-A | Stabilized compositions of pegylated carfilzomib compounds | 美国安进公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190142957-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3464277-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | Amgen Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205392-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, FCGRT, MAN2B1 | CFD 2455/4885PTGS1 1495/4885CYP4F2 3786/4885 |
| US-20190142957-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | CFD 884/4885PTGS1 2346/4885CYP4F2 3956/4885 |
| US-20230048560-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | CFD 884/4885PTGS1 2346/4885CYP4F2 3956/4885 |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | FCGRT, EPOR, MCL1 | CFD 2561/4885PTGS1 1657/4885CYP4F2 3588/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | CFD 2561/4885PTGS1 1657/4885CYP4F2 3588/4885 |
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | CFD 884/4885PTGS1 2346/4885CYP4F2 3956/4885 |
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | CFD 2561/4885PTGS1 1657/4885CYP4F2 3588/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | CFD 2561/4885PTGS1 1657/4885CYP4F2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.